Voluntary wheel running can lead to modulation of immune checkpoint molecule expression

References

• Christensen JF, Simonsen C, Hojman P. Exercise training in cancer control and treatment. Compr Physiol. 2018;13:165–205.
   Web of Science ®Google Scholar
• Hojman P, Gehl J, Christensen JF, et al. Molecular mechanisms linking exercise to cancer prevention and treatment. Cell Metab. 2018;27:10–21.
   PubMed Web of Science ®Google Scholar
• Betof AS, Lascola CD, Weitzel D, et al. Modulation of murine breast tumor vascularity, hypoxia, and chemotherapeutic response by exercise. J Natl Cancer Inst. 2015;107:1–5.
   Google Scholar
• Pedersen L, Idorn M, Olofsson G, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23:554–562.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–214.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461.
   PubMed Web of Science ®Google Scholar
• Herbst R, Soria J, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder J, Fine G, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody pembrolizumab in melanoma. J Cin Oncol. 2016;34:4102–4109.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavli AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–1835.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long G, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, et al. The “cancer immunogram”. Science. 2016;352:658–660.
   PubMed Web of Science ®Google Scholar
• Ruiz-Casado A, Martín-Ruiz A, Pérez LM, et al. Exercise and the hallmarks of cancer. Trends Cancer. 2017;3:423–441.
   PubMed Web of Science ®Google Scholar
• Martín-Ruiz A, Fiuza-Luces C, Rincón-Castanedo C, et al. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. Cancer Metastasis Rev. 2020;39:115–115.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
   PubMed Web of Science ®Google Scholar
• Iwanowicz LR, Densmore CL, Ottinger CA. Calcein AM release-based cytotoxic cell assay for fish leukocytes. Fish Shell Fish Immunol. 2004;16:127–137.
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–452.
   PubMed Web of Science ®Google Scholar
• Pedersen KS, Gatto F, Zerahn B, et al. Exercise-mediated lowering of glutamine availability suppresses tumor growth and attenuates muscle wasting. iScience. 2020;23:100978.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–268.
   PubMed Web of Science ®Google Scholar
• Neri S, Mariani E, Meneghetti A, et al. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol. 2001;8:1131–1135.
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Schneider G, Schmidt-Supprian M, Rad R, et al. Tissue-specific tumorigenesis – context matters. Nat Rev Cancer. 2018;17:239–253.
   Web of Science ®Google Scholar
• Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313–326.
   PubMed Web of Science ®Google Scholar
• Lau J, Cheung J, Navarro A, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:1–11.
   PubMed Web of Science ®Google Scholar
• Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904.
   PubMed Web of Science ®Google Scholar
• Kleinovink JW, Marijt KA, Schoonderwoerd MJA, et al. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology. 2017;6:e1294299.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–287.
   PubMed Web of Science ®Google Scholar
• Dong W, Wu X, Ma S, et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 2019;626:CD-18–1259.
   Google Scholar
• Olson B, Li Y, Lin Y, et al. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8:1358–1364.
   PubMed Web of Science ®Google Scholar
• Omori R, Eguchi J, Hiroishi K, et al. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors. Cancer Gene Ther. 2012;19:637–643.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice . J Clin Invest. 2014;124:687–695.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–543.
   PubMed Web of Science ®Google Scholar